Tags

Type your tag names separated by a space and hit enter

Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis.
Scand J Rheumatol. 2020 Jul; 49(4):281-291.SJ

Abstract

OBJECTIVES

The discovery of diseased tissue-specific neoantigens offers the opportunity to develop important disease tissue-specific biomarkers that can help in the prediction, diagnosis, and stratification of diseases. This opportunity is specifically significant for autoimmune diseases where diagnostic biomarkers are not available. Inflammatory autoimmune diseases are commonly associated with local generation of large amounts of reactive oxidants. We have previously identified oxidative post-translationally modified (oxPTM) tissue-specific neoantigens in rheumatoid arthritis (RA) and type 1 diabetes that elicit an immune response. In the current study, we studied the presence and clinical significance of antibodies to oxPTM collagen type II (CII) in patients with spondyloarthritis (SpA).

METHOD

Levels of antibodies specific to native CII and oxPTM-CII were assessed by enzyme-linked immunosorbent assay.

RESULTS

Immunoglobulin G (IgG) binding to oxPTM-CII was observed in 52%, 83%, and 28% of serum samples from patients with axial spondyloarthritis (axSpA), RA, and psoriatic arthritis (PsA), respectively. Importantly, while strong IgA anti-oxPTM-CII responses were detected in axSpA and PsA patients, with 47% and 84% respective binders, no IgA anti-oxPTM-CII was detected in RA patients. IgA anti-oxPTM-CII reactivity in axSpA patients treated with biologics was higher and more frequent, with 85% binders compared to 9% binders in patients treated with synthetic disease-modifying anti-rheumatic drugs.

CONCLUSION

Our data imply that SpA and PsA are associated with the presence of antibodies to oxPTM-CII, suggesting that there may be a humoral component that may distinguish patients with SpA from RA. Our approach could be adapted to other diseases, particularly to inflammatory autoimmune diseases.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Vinci C
Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London , London, UK. Department of Endocrinology and Diabetes, Campus Biomedico , Rome, Italy.
Infantino M
Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital , Florence, Italy.
Raturi S
Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London , London, UK.
Tindell A
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow, UK.
Topping LM
Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London , London, UK.
Strollo R
Department of Endocrinology and Diabetes, Campus Biomedico , Rome, Italy.
Amital H
Department of Internal Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Centre , Ramat Gan, Israel.
Shoenfeld Y
Department of Internal Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Centre , Ramat Gan, Israel.
Gertel S
Department of Internal Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Centre , Ramat Gan, Israel.
Grossi V
Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital , Florence, Italy.
Manfredi M
Immunology and Allergology Laboratory Unit, S.Giovanni di Dio Hospital , Florence, Italy.
Rutigliano IM
Rheumatology Unit, Sab.Giovanni di Dio Hospital , Florence, Italy.
Bandinelli F
Rheumatology Unit, Sab.Giovanni di Dio Hospital , Florence, Italy.
Li Gobbi F
Rheumatology Unit, Sab.Giovanni di Dio Hospital , Florence, Italy.
Damiani A
Rheumatology Unit, Sab.Giovanni di Dio Hospital , Florence, Italy.
Pozzilli P
Department of Endocrinology and Diabetes, Campus Biomedico , Rome, Italy.
Mcinnes IB
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow, UK.
Goodyear CS
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow , Glasgow, UK.
Benucci M
Rheumatology Unit, Sab.Giovanni di Dio Hospital , Florence, Italy.
Nissim A
Biochemical Pharmacology, William Harvey Research Institute, Queen Mary University of London , London, UK.

MeSH

AdultAgedAged, 80 and overArthritis, PsoriaticArthritis, RheumatoidBiomarkersCase-Control StudiesCollagen Type IIDiagnosis, DifferentialFemaleHumansImmunoglobulin AMaleMiddle AgedOxidation-ReductionProtein Processing, Post-TranslationalSpondylarthropathies

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

32314641

Citation

Vinci, C, et al. "Immunoglobulin a Antibodies to Oxidized Collagen Type II as a Potential Biomarker for the Stratification of Spondyloarthritis From Rheumatoid Arthritis." Scandinavian Journal of Rheumatology, vol. 49, no. 4, 2020, pp. 281-291.
Vinci C, Infantino M, Raturi S, et al. Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. Scand J Rheumatol. 2020;49(4):281-291.
Vinci, C., Infantino, M., Raturi, S., Tindell, A., Topping, L. M., Strollo, R., Amital, H., Shoenfeld, Y., Gertel, S., Grossi, V., Manfredi, M., Rutigliano, I. M., Bandinelli, F., Li Gobbi, F., Damiani, A., Pozzilli, P., Mcinnes, I. B., Goodyear, C. S., Benucci, M., & Nissim, A. (2020). Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. Scandinavian Journal of Rheumatology, 49(4), 281-291. https://doi.org/10.1080/03009742.2020.1713395
Vinci C, et al. Immunoglobulin a Antibodies to Oxidized Collagen Type II as a Potential Biomarker for the Stratification of Spondyloarthritis From Rheumatoid Arthritis. Scand J Rheumatol. 2020;49(4):281-291. PubMed PMID: 32314641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. AU - Vinci,C, AU - Infantino,M, AU - Raturi,S, AU - Tindell,A, AU - Topping,L M, AU - Strollo,R, AU - Amital,H, AU - Shoenfeld,Y, AU - Gertel,S, AU - Grossi,V, AU - Manfredi,M, AU - Rutigliano,I M, AU - Bandinelli,F, AU - Li Gobbi,F, AU - Damiani,A, AU - Pozzilli,P, AU - Mcinnes,I B, AU - Goodyear,C S, AU - Benucci,M, AU - Nissim,A, Y1 - 2020/04/21/ PY - 2020/4/22/pubmed PY - 2020/10/6/medline PY - 2020/4/22/entrez SP - 281 EP - 291 JF - Scandinavian journal of rheumatology JO - Scand J Rheumatol VL - 49 IS - 4 N2 - OBJECTIVES: The discovery of diseased tissue-specific neoantigens offers the opportunity to develop important disease tissue-specific biomarkers that can help in the prediction, diagnosis, and stratification of diseases. This opportunity is specifically significant for autoimmune diseases where diagnostic biomarkers are not available. Inflammatory autoimmune diseases are commonly associated with local generation of large amounts of reactive oxidants. We have previously identified oxidative post-translationally modified (oxPTM) tissue-specific neoantigens in rheumatoid arthritis (RA) and type 1 diabetes that elicit an immune response. In the current study, we studied the presence and clinical significance of antibodies to oxPTM collagen type II (CII) in patients with spondyloarthritis (SpA). METHOD: Levels of antibodies specific to native CII and oxPTM-CII were assessed by enzyme-linked immunosorbent assay. RESULTS: Immunoglobulin G (IgG) binding to oxPTM-CII was observed in 52%, 83%, and 28% of serum samples from patients with axial spondyloarthritis (axSpA), RA, and psoriatic arthritis (PsA), respectively. Importantly, while strong IgA anti-oxPTM-CII responses were detected in axSpA and PsA patients, with 47% and 84% respective binders, no IgA anti-oxPTM-CII was detected in RA patients. IgA anti-oxPTM-CII reactivity in axSpA patients treated with biologics was higher and more frequent, with 85% binders compared to 9% binders in patients treated with synthetic disease-modifying anti-rheumatic drugs. CONCLUSION: Our data imply that SpA and PsA are associated with the presence of antibodies to oxPTM-CII, suggesting that there may be a humoral component that may distinguish patients with SpA from RA. Our approach could be adapted to other diseases, particularly to inflammatory autoimmune diseases. SN - 1502-7732 UR - https://www.unboundmedicine.com/medline/citation/32314641/Immunoglobulin_A_antibodies_to_oxidized_collagen_type_II_as_a_potential_biomarker_for_the_stratification_of_spondyloarthritis_from_rheumatoid_arthritis_ DB - PRIME DP - Unbound Medicine ER -